Delving into the Latest Updates on SR-0379 with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Target

Akt-1 x Class I PI3K x mTOR

Action

inhibitors

Mechanism

Akt-1 inhibitors(Serine/threonine-protein kinase AKT1 inhibitors), Class I PI3K inhibitors(PI3-kinase class I inhibitors), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors)

Therapeutic Areas

Skin and Musculoskeletal Diseases

Active Indication

Skin Ulcer

Inactive Indication

Pressure Ulcer

Originator Organization

FunPep Co., Ltd.

Active Organization

FunPep Co., Ltd.

Shionogi & Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC121H222N42O21S2

InChIKeyIVQFHGVEBLGBEL-RQEVABAPSA-N

CAS Registry1639363-19-1

Sequence Code 1495702

Ischemia is a serious disease, characterized by an inadequate blood supply to an organ or part of the body. In the present study, we evaluated the effects of the anti-microbial peptide SR-0379 on the stem cell-mediated therapy of ischemic diseases. The migratory and tube-forming abilities of human endothelial progenitor cells (EPCs) were enhanced by treatment with SR-0379 in vitro. Intramuscular administration of SR-0379 into a murine ischemic hindlimb significantly enhanced blood perfusion, decreased tissue necrosis, and increased the number of blood vessels in the ischemic muscle. Moreover, co-administration of SR-0379 with EPCs stimulated blood perfusion in an ischemic hindlimb more than intramuscular injection with either SR-0379 or EPCs alone. This enhanced blood perfusion was accompanied by a significant increase in the number of CD31- and α-SMApositive blood vessels in ischemic hindlimb. These results suggest that SR-0379 is a potential drug candidate for potentiating EPC-mediated therapy of ischemic diseases. [BMB Reports 2017; 50(10): 504-509].

Bio Industry

Development of a novel multifunctional peptide with wound healing and antimicrobial activities

Author: Nakagami, Hironori ; Morishita, Ryuichi ; Tenma, Akiko ; Tomioka, Hideki

An antibacterial peptide is one of the natural immunity functions charged with the role of possessing an antibacterial spectrum in a wide area and protecting a living body as a living body defense organization.The one which indicates various ways as well as an antibacterial way in the antibacterial peptide exists, but a peptide of multiple functions with the wound healing effect and an antibacterial activity was found in the process of the genetic function screening.

PLoS ONEQ3 · CROSS-FIELD

Novel Anti-Microbial Peptide SR-0379 Accelerates Wound Healing via the PI3 Kinase/Akt/mTOR Pathway

Q3 · CROSS-FIELD

ArticleOA

Author: Saito, Yoshimi ; Tenma, Akiko ; Kaneda, Yasufumi ; Tomono, Kazunori ; Morishita, Ryuichi ; Nakagami, Hironori ; Kanamori, Toshihide ; Tomioka, Hideki ; Tamura, Nao ; Kaga, Toshihiro

We developed a novel cationic antimicrobial peptide, AG30/5C, which demonstrates angiogenic properties similar to those of LL-37 or PR39. However, improvement of its stability and cost efficacy are required for clinical application. Therefore, we examined the metabolites of AG30/5C, which provided the further optimized compound, SR-0379. SR-0379 enhanced the proliferation of human dermal fibroblast cells (NHDFs) via the PI3 kinase-Akt-mTOR pathway through integrin-mediated interactions. Furthermore SR-0379 promoted the tube formation of human umbilical vein endothelial cells (HUVECs) in co-culture with NHDFs. This compound also displays antimicrobial activities against a number of bacteria, including drug-resistant microbes and fungi. We evaluated the effect of SR-0379 in two different would-healing models in rats, the full-thickness defects under a diabetic condition and an acutely infected wound with full-thickness defects and inoculation with Staphylococcus aureus. Treatment with SR-0379 significantly accelerated wound healing when compared to fibroblast growth factor 2 (FGF2). The beneficial effects of SR-0379 on wound healing can be explained by enhanced angiogenesis, granulation tissue formation, proliferation of endothelial cells and fibroblasts and antimicrobial activity. These results indicate that SR-0379 may have the potential for drug development in wound repair, even under especially critical colonization conditions.

2

News (Medical) associated with SR-0379

19 Aug 2021

·www.funpep.co.jp

Announcing the Start of Administration of Functional Peptide SR-0379 to Subjects in Phase III Clinical Trial

August 19,2021 Press Release August 13,2021 Press Release June 16,2021 Press Release June 1,2021 Press Release January 29,2021 Press Release

Phase 3Phase 2INDClinical Trial Termination

29 Oct 2015

·www.funpep.co.jp

Shionogi and FunPep Enter into a Licensing Agreement on the Functional Peptide which Accelerates Wound-healing, SR-0379

Press Release Information 2024 2023 2022 2021 2020 2019 2018 2016 2015 October 29,2015 Press Release

License out/inPDC

100 Deals associated with SR-0379

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Skin Ulcer	Phase 3	Japan	FunPep Co., Ltd.	30 Jan 2022
Skin Ulcer	Phase 3	Japan	Shionogi & Co., Ltd.	30 Jan 2022
Pressure Ulcer	Discovery	Japan	Shionogi & Co., Ltd.	27 Jun 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data